The remaining 7 patients (64%), BLA was used as the first-line treatment for ECS in 4 patients, where they had uncontrollable hypercortisolism, compression fractures, concomitant PHEO, and absence of a site of paraneoplastic ACTH secretion. The gene discussed is POMC; the disease is adrenal gland hyperfunction.